Ariana Pharma is a leading digital health company focused on developing advanced therapeutic decision support systems

Ariana Pharma’s Artificial Intelligence, KEM®
13/12/2018
Oncodesign (booth #2744) & Ariana Pharma will participate to AACR 2019; March 29 – April 3, Atlanta, Georgia, USA
13/12/2018

Ariana Pharma is a leading digital health company focused on developing advanced therapeutic decision support systems

Ariana Pharma is a leading digital health Company focused on developing advanced therapeutic decision support systems


Ariana Pharma demonstrates use of Artificial intelligence and PDX mouse models to simulate clinical trial and identify biomarkers of response for combination therapy.

Ariana’s innovative clinical data analysis and diagnostic testing solutions help the healthcare sector better adapt patient treatments to individual biological characteristics.

Ariana's KEM® Artificial Intelligence technology enables personalization of therapies, improves the efficacy and safety of patient treatment, reduces risks and drug development costs, and accelerates time to market. With a growing number of successful therapeutic development applications, KEM® is the only FDA-reviewed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine.

At Ariana, we have a 15 years track record of increasing success rates in clinical trials, using our advanced Artificial Intelligence technology KEM®. We identify best patients that can benefit from a therapy and optimal Endpoints that capture its benefit.

Using our KEM® AI platform, we help our clients identify best targets and biomarkers combining multiple data sources, design their personalized medicine clinical trial, collect-omic data and identify best endpoints that capture impact of a given drug and best biomarkers that can help select responder patients and exclude non-responders, and present innovative and Fast Track approaches to the FDA.

Combining our data analytics with our regulatory expertise, we help fast track clinical trials into the Precision Medicine realm.
The technology can be applied as early as a phase 1(ValirX case study) or phase 2 ( Anavex Life Sciences case study.), when limited number of patients are available. It can also be used in larger Phase III (Pierre Fabre case study) trials or in the analysis of Real-World Evidence databases using our database of 135M patients (Sanofi case study)

Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology treatment selection system that combines both DNA and RNA.

Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company opened a subsidiary in the United States in 2012. Further information is available at www.arianapharma.com.

Share this